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Abstract
Background: Chronic viral hepatitis B remains a global public health concern. Currently, several drugs, such as
lamivudine and telbivudine, are recommended for treatment of patients with chronic hepatitis B. However, there
are no conclusive results on the comparison of the efficacy of lamivudine (LAM) and telbivudine (LdT) in the
treatment of chronic hepatitis B.
Results: To evaluate the comparison of the efficacy of LAM and LdT in the treatment of chronic hepatitis B by a
systematic review and meta-analysis of clinical trials, we searched PUBMED (from 1990 to April 2010), Web of
Science (from 1990 to April 2010), EMBASE (from 1990 to April 2010), CNKI (National Knowledge Infrastructure)
(from 1990 to April 2010), VIP database (from 1990 to April 2010), WANFANG database (from 1990 to April 2010),
the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Review. At the end of
one-year treatment, LdT was better than LAM at the biochemical response, virological response, HBeAg loss,
therapeutic response, while less than at the viral breakthrough and viral resistance, but there was no significant
difference in the HBeAg seroconversion and HBsAg response. LdT was better than LAM at the HBeAg
seroconversion with prolonged treatment to two years.
Conclusions: In summary, LdT was superior in inhibiting HBV replication and preventing drug resistance as
compared to LAM for CHB patients. But LdT may cause more nonspecific adverse events and can lead to more CK
elevation than LAM. It is thus recommended that the LdT could be used as an option for patients but adverse
events, for example CK elevation, must be monitored.
Background
Chronic hepatitis B virus (HBV) infection is a serious
global public health problem associated with cirrhosis,
liver failure and hepatocellular carcinoma (HCC) [1]. Of
the two billion people who have been infected, more
than 350 million have chronic hepatitis[2]. It is esti-
mated that between 235,000 and 328,000 people die
annually due to liver cirrhosis and hepatocellular carci-
noma, respectively[3]. Currently, several drugs are
recommended for treatment of patients with chronic
hepatitis B. These drugs can be divided into two main
groups based on their mechanism of action, namely
immunomodulatory drugs like alpha interferons and
anti-viral drugs including lamivudine, adefovir, entecavir,
tenofovir, and telbivudine[4].
LdT was approved by the US Food and Drug Admin-
istration (FDA) on October 25, 2006. It is an L-nucleo-
side that is structurally related to lamivudine and highly
selective for hepatitis B virus DNA and inhibits viral
DNA synthesis with no effect on human DNA or other
viruses[5]. In the woodchuck model of HBV infection,
viral replication was inhibited within the first few days
of treatment and was maintained throughout the treat-
ment period. Then viral rebound with pretreatment
levels between week 4 and week 8[5]. A placebo-con-
trolled dose-escalation trial investigated daily dosing
levels of LdT between 25 and 800 mg/day for 4 weeks.
This study showed that LdT induced striking dose-
related suppression of serum HBV DNA levels and a
nearly maximal viral load reduction was obtained at
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dosages of 400-800 mg/day[6]. One-year data from the
GLOBE study has recently been presented[7]. Among
patients with HBeAg-positive chronic hepatitis B, the
rates of HBeAg seroconversion, virological response and
HBeAg response were nonsignificantly higher in patients
treated with LdT than in patient treated with LAM[7-9].
However other trials did not support this result[10,11].
And recently, some randomized controlled clinical trials
compared the efficacy of LAM and LdT in the treatment
of chronic hepatitis B and had different results. Thus,
we conducted this systematic review of these trials to
assess the evidence obtained on the efficacy of LdT
treatment in chronic HBV infection.
Methods
Search strategy
We searched the following databases until April 2010:
PUBMED (from 1990 to April 2010), Web of Science
(from 1990 to April 2010), EMBASE (from 1990 to
April 2010), CNKI (National Knowledge Infrastructure)
(from 1990 to April 2010), VIP database (from 1990 to
April 2010), WANFANG database (from 1990 to April
2010), the Cochrane Central Register of Controlled
Trials and the Cochrane Database of Systematic Review.
Of these databases, CNKI, WANFANG and VIP data-
bases provide literatures in Chinese. The search process
was designed to find initially all trials involving terms:
“Hepatitis B”, “lamivudine”, “telbivudine”,"randomized
controlled trial” (and multiple synonyms for each term).
Reference lists from retrieved documents were also
searched. Computer searches were supplemented with a
manual search. Search results were downloaded to a
reference database and further screened. Two authors
(S. S. Zhao and L. H. Tang) independently screened all
citations and abstracts identified by the search strategy
to identify potentially eligible studies.
Types of studies
All relevant randomised clinical trials will be included,
irrespective of language, or blinding. Quasi-randomised
studies, which use quasi-random method of allocating
participants to different interventions, and observational
studies will be excluded except for their report on
harms.
Types of participants
Male or female patients, of any age or ethnic origin,
who have chronic hepatitis B, defined as chronic hepati-
tis B virus infection with evidence of hepatitis (alanine
aminotransferase (ALT) elevation of at least one and a
half times the upper limit of normal range) and of viral
replication (detectable hepatitis B virus DNA by DNA
hybridisation method or polymerase chain reaction
(PCR)), will be included. Patients with cirrhosis,
decompensated liver disease, HIV, hepatocellular carci-
noma, prior liver transplantation and concomitant renal
failure was excluded.
Types of interventions
The comparisons will include lamivudine versus
telbivudine.
Types of outcome measures
Proportion of patients with biochemical response, viro-
logical response, HBeAg seroconversion, HBeAg loss,
therapeutic response, HBsAg response, creatine kinase
(CK) elevation at the end of one-year treatment or two-
year treatment.
Data extraction
Data was extracted independently by both authors (S. S.
Zhao and L. H. Tang) using a pre-designed data extrac-
tion form and the information subsequently was entered
into Review Manager (RevMan 5.0). Information was
extracted on data source; eligibility; methods; partici-
pants (age range, exclusion criteria, sample size, gender);
interventions; and results. We resolved any discrepancies
between the extracted data by discussion, and, if
required, referral to the third author (R. R. Zhou).
Where data were not clear or not presented by the
author in the publication, we attempted to contact the
trial author for further details.
Quality assessment
Quality of the trials was assessed using the QUOROM
guidelines as well as using the Jadad scale[12].
Data analysis
Data analysis was carried out with the use of Review
Manager Software 5.0(Cochrane Collaboration, Oxford,
United Kingdom). For each eligible study, dichotomous
data were presented as relative risk (RR), which is the
probability that a member of an exposed group will
develop a disease relative to the probability that a mem-
ber of an unexposed group will develop that same dis-
ease, and continuous outcomes were presented as
weighted mean difference (WMD), which is calculated
as the difference between the mean value in the treat-
ment and control groups, both with 95% confidence
intervals (CI). Meta-analysis was performed using fixed-
effect or random-effect methods, depending on the
absence or presence of significant heterogeneity. Statisti-
cal heterogeneity between trials was evaluated by the
chi-square and I-square (I2) tests, with significance set
at P < 0.10. In the absence of statistically significant het-
erogeneity, the fixed-effect method was used to combine
the results. When heterogeneity was confirmed (P <
0.10), the random-effect method was used. Additionally,
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sensitivity analysis should be carried out if low quality
trials were included. The overall effect was tested using
z scores calculated by Fisher’s z’ transformation, with
significance set at P < 0.05.
Results
We searched relevant literatures, and finally a total of
171 studies identified by the searches(PUBMED:8; Web
of Science:12; EMBASE:37; CNKI:42; VIP database:18;
WANFANG database:33; the Cochrane Central Register
of Controlled Trials and the Cochrane Database of Sys-
tematic Review:21). By scanning titles and abstracts, 142
redundant publications, review, and meta-analysis were
excluded. After referring to full texts, 18 studies that did
not satisfy the inclusion criteria were removed from
consideration. Eleven studies were left for analysis which
involved 2964 patients in total [6-11,13-17], of whom
1475 were included in LAM groups and 1489 were
included in LdT groups. According to treatment period,
we divided the studies into two subgroups: one-year
treatment group[6-11,13,14] and two-year treatment
group[15-17]. In addition, all studied populations with
comparable baseline characteristics between LAM
groups and LdT groups. Of the eleven trials, six were
published in English[6,7,10,15-17] and the others were
published in Chinese[8,9,11,13,14]. The detailed infor-




Only seven trials[6-8,10,11,13,14] demonstrated the bio-
chemical response rate in this subgroup. According to
chi-squared statistic and I square (I2), heterogeneity was
assessed and had significant differences[Tau2 = 0.01;
Chi2 = 13.46, df = 6 (P = 0.04); I2 = 55%]. A summary
estimate of the relative risk of LdT versus LAM by use
of a random-effects approach. The results of the seven
trials showed normalization rates for ALT in the LdT
group as 81.2%, compared to 75.8% in the LAM group
after one-year treatment. And the biochemical response
rates in LdT group was higher than LAM group[RR =
1.13, 95%CI(1.04-1.22), P = 0.003](Figure 1). When a
study[7] was removed, the heterogeneity was assessed
and not found to be a concern[Chi2 = 0.88, df = 5 (P =
0.97); I2 = 0%]. The difference in response rate between
two group were still significantly by use a fixed effects
model[87.5% vs. 74.8%, RR = 1.17, 95%CI (1.10-1.25), P
< 0.00001].
Two-year treatment group
Only four trials[13,15-17] demonstrated the biochemical
response rate in this subgroup. According to chi-
squared statistic and I square (I2 ), heterogeneity was
assessed and not found to be a concern[Chi2 = 3.06, df
= 3 (P = 0.38); I2 = 2%]. The biochemical response rates
in LdT group was higher as compared with that in
LAM group [73.4% vs. 63.9%, RR = 1.15, 95%CI (1.09-
1.21), P < 0.00001] (Figure 2). Additionally, when low-
quality study[13] was removed, the difference in
response rate was still statistically significantly[73.0% vs.
63.9%, RR = 1.14, 95%CI (1.08-1.21), P < 0.00001].
Virological response
One-year treatment group
Eight trials[6-11,13,14] demonstrated the virological
response rate in this subgroup. According to chi-
squared statistic and I square (I2), heterogeneity was
assessed and had significant differences[Tau2 = 0.09;
Chi2 = 32.88, df = 7 (P < 0.0001); I2 = 79%]. A summary
estimate of the relative risk of LdT versus LAM by use
of a random-effects approach. The results of the eight
trials showed virological response rate in the LdT group
as 41.6%, compared to 28.3% in the LAM group after
one-year treatment. And the virological response rates
Table 1 Description of included randomized controlled trials
Study Study design Grade Treatment options Study location dosage of drugs Treatment
LAM LdT
Lai 2005[6] RCT, DB 5 LAM vs LdT Global 100 mg 400/600 mg 12 months
Lai 2007[7] RCT, DB 5 LAM vs LdT Global 100 mg 600 mg 12 months
Rasenack 2007[17] RCT, DB 4 LAM vs LdT Global 100 mg 600 mg 24 months
Jia 2007[16] RCT, DB 4 LAM vs LdT China 100 mg 600 mg 24 months
Hou 2008[10] RCT, DB 4 LAM vs LdT China 100 mg 600 mg 12 months
Liaw 2009[15] RCT, DB 5 LAM vs LdT Global 100 mg 600 mg 24 months
Cai 2009[13] RCT, DB 5 LAM vs LdT China 100 mg 600 mg 12 months
Yang 2009[14] RCT 3 LAM vs LdT China 100 mg 600 mg 12 months
Zhong 2009[11] RCT 3 LAM vs LdT China 100 mg 600 mg 12 months
Chen 2009[9] N/A 2 LAM vs LdT China 100 mg 600 mg 12 months
Tang 2009[8] RCT 3 LAM vs LdT China 100 mg 600 mg 12 months
RCT, randomized controlled trial; DB, double blind; LAM, Lamivudine; LdT, Telbivudine
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in LdT group was higher than LAM group[RR = 1.50,
95%CI(1.16-1.94), P = 0.002](Figure 3). When a study
[10] was removed, the heterogeneity was assessed and
not found to be a concern[Chi2 = 3.91, df = 6 (P =
0.69); I2 = 0%]. The difference in response rate between
two group were still significantly by use a fixed effects
model[35.5% vs. 28.9%, RR = 1.26, 95%CI (1.10-1.45), P
= 0.001].
Two-year treatment group
Four trials[13,15-17] demonstrated the virological
response rate in this subgroup. According to chi-
squared statistic and I square (I2 ), heterogeneity was
assessed and not found to be a concern[Chi2 = 0.97,
df = 3 (P = 0.81); I2 = 0%], allowing use of the fixed
effect model for meta-analysis. The results of the four
studies showed the virological response rate for the LdT
group was 63.5%, while the LAM group response rate
was 43.6%. The difference of virological response rates
at the end of two years between the two group was sta-
tistically significant[RR = 1.46, 95%CI (1.35-1.58), P <
0.00001] (Figure 4). Additionally, when a study[16] was
removed, the difference in response rate was still statis-
tically significantly[63.7% vs. 44.3%, RR = 1.44, 95%CI
(1.32-1.56), P < 0.00001]. So compared to the LAM
group, LdT group was more effective as measured by
virological response.
Table 2 Characteristics of included clinical trials in systematic review
Study Entry e status Sample size (n) Sex Median (range) age (y) Mean (range) weight (kg) Intervention
Male Female LAM LdT LAM LdT LAM LdT
Lai 2005[6] HBeAg+ 63 49 14 34 (18-61) 40 (19-60) 69 (45-86) 70 (53-120) 19 44
HBeAg- N/A N/A N/A N/A 41 (22-68) N/A 70 (51-96) N/A N/A
Lai 2007[7] HBeAg+ 921 684 237 33 (16-67) 32 (16-63) 68 (38-150) 66 (38-126) 463 458
HBeAg- 446 351 95 43 (18-68) 43 (17-68) 71 (45-148) 72 (42-123) 224 222
Rasenack 2007[17] HBeAg+ 580 N/A N/A N/A N/A N/A N/A 289 291
Jia 2007[16] HBeAg+ 290 225 65 29 (15-63) 28 (16-64) 62 (42-96) 62 (43-93) 143 147
HBeAg- 42 36 6 36 (19-58) 38 (20-56) 65 (49-93) 64 (52-99) 22 20
Hou 2008[10] HBeAg+ 290 225 65 29 (15-63) 28 (16-64) 62 (42-96) 62 (43-93) 143 147
HBeAg- 42 36 6 36 (19-58) 38 (20-56) 65 (49-93) 64 (52-99) 22 20
Liaw 2009[15] HBeAg+ 921 684 237 33 (16-67) 32 (16-63) 68 (38-150) 66 (38-126) 463 458
HBeAg- 446 351 95 43 (18-68) 43 (17-68) 71 (45-148) 72 (42-123) 224 222
Cai 2009[13] HBeAg+ 36 34 11 33.62 ± 11.17 29.59 ± 10.17 N/A N/A 19 17
HBeAg- 9 N/A N/A 4 5
Yang 2009[14] HBeAg+ 40 62 38 47.9 ± 8.6 N/A N/A 50 50
HBeAg- 60 N/A N/A
Zhong 2009[11] HBeAg+ 120 81 39 30 ± 8.5 29 ± 8.2 61 ± 13.6 62 ± 14.2 60 60
HBeAg- 120 72 48 42 ± 9.5 41 ± 10.1 64 ± 15.2 63 ± 14.5 60 60
Chen 2009[9] HBeAg+ 73 62 11 27.9(16-46) N/A N/A 43 30
Tang 2009[8] HBeAg+ 108 N/A N/A N/A N/A N/A N/A 52 56
HBeAg- 56 N/A N/A N/A N/A N/A N/A 27 29
Figure 1 Effect of telbivudine vs. lamivudine at the end of one-year treatment on Biochemical response.
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HBeAg seroconversion
One-year treatment group
Seven[6-8,10,11,13,14] trials demonstrated the HBeAg
seroconversion rate in this subgroup. According to chi-
squared statistic and I square (I2 ), heterogeneity was
assessed and not found to be a concern[Chi2 = 2.65, df
= 6 (P = 0.85); I2 = 0%], allowing use of the fixed effect
model for meta-analysis. The results of the seven studies
showed the virological response rate for the LdT group
was 25.0%, while the LAM group response rate was
21.2%. The difference of HBeAg seroconversion rates at
the end of one year between the two group was similar
[RR = 1.19, 95%CI (0.99-1.42), P = 0.06] (Figure 5).
Moreover, when low-quality study[9] was removed, the
difference in HBeAg seroconversion rate was still no sta-
tistically significant[24.7% vs. 20.9%, RR = 1.44, 95%CI
(1.32-1.56), P < 0.00001].
Two-year treatment group
Four trials[13,15-17] demonstrated the HBeAg serocon-
version rate in this subgroup. According to chi-squared
statistic and I square (I2 ), heterogeneity was assessed
and not found to be a concern[Chi2 = 1.00, df = 3 (P =
0.80); I2 = 0%]. The results of the four studies showed
the HBeAg seroconversion rate for the LdT group was
32.0%, while the LAM group response rate was 24.8%.
The difference of HBeAg seroconversion rates at the
end of two years between the two group was statistically
significant[RR = 1.29, 95%CI (1.11-1.50), P < 0.0007]
(Figure 6). Additionally, when a study[17] was removed,
the difference in HBeAg seroconversion rate was still
statistically significantly[29.7% vs. 23.7%, RR = 1.25, 95%
CI (1.04-1.51), P = 0.02]. So LdT group was similar with
LAM group with respect to seroconversion of HBeAg
after one year treatment, but more effective at the end
of two years treatment.
HBeAg loss
One-year treatment group
The rate of HBeAg loss at the end of the one-year treat-
ment is shown in Figure 7. The results of the seven stu-
dies[6-11,13] showed the HBeAg loss rate of LdT group
was 29.8%, while the LAM group rate was 23.7%. There
was on statistical heterogeneity(Chi2 = 4.18, df = 6 (P =
0.65); I2 = 0%), and fixed effect model was used. The
difference of the HBeAg loss rates at the end of the
one-year treatment between the two group achieved sta-
tistical significance[RR = 1.26, 95%CI (1.07-1.48), P =
0.005] (Figure 7). Additionally, when low-quality study
Figure 2 Effect of telbivudine vs. lamivudine at the end of two-year treatment on Biochemical response.
Figure 3 Effect of telbivudine vs. lamivudine at the end of one-year treatment on Virological response.
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[11] was removed, the difference in HBeAg loss rate was
still statistically significantly[28.8% vs. 23.6%, RR = 1.22,
95%CI (1.03-1.44), P = 0.02].
Two-year treatment group
According to chi-squared statistic and I square (I2 ), het-
erogeneity was assessed and not found to be a concern
[Chi2 = 0.99, df = 3 (P = 0.80); I2 = 0%]. The results of
the four studies[13,15-17] showed the HBeAg loss rate
for the LdT group was 38.1%, while the LAM group
response rate was 29.9%. The difference of HBeAg loss
rates at the end of two years between the two group
was statistically significant[RR = 1.27, 95%CI (1.12-1.45),
P = 0.0002] (Figure 8). Additionally, when a effective
study[17] was removed, the difference in HBeAg loss
rate was still statistically significantly[36.47% vs. 29.0%,
RR = 1.25, 95%CI (1.07-1.47), P = 0.006].
Therapeutic response
One-year treatment group
Only five trials[6,7,10,11,14] demonstrated the therapeu-
tic response rate in this subgroup. According to chi-
squared statistic and I square (I2), heterogeneity was
assessed and had significant differences[Tau2 = 0.01;
Chi2 = 12.59, df = 4 (P = 0.01); I2 = 68%]. A summary
estimate of the relative risk of LdT versus LAM by use
of a random-effects approach. The results of the five
trials showed therapeutic response rates in the LdT
group as 77.5%, compared to 68.2% in the LAM group
after one-year treatment. And the therapeutic response
rates in LdT group was higher than LAM group[RR =
1.21, 95%CI(1.07-1.37), P = 0.003] (Figure 9). When
low-quality study[11] was removed, the heterogeneity
was assessed and was still a concern[Tau2 = 0.02; Chi2 =
11.95, df = 3 (P = 0.008); I2 = 75%]. The difference in
response rate between two group were still significantly
by use a random-effects model[77.8% vs. 69.1%, RR =
1.22, 95%CI (1.04-1.43), P < 0.01].
Two-year treatment group
According to chi-squared statistic and I square (I2 ), het-
erogeneity was assessed and had significant differences
[Chi2 = 4.74, df = 2 (P = 0.09); I2 = 58%]. The results of
the three studies[15-17] showed the therapeutic
response rate for the LdT group was 67.9%, while the
LAM group response rate was 52.1%. The difference of
therapeutic response rates at the end of two years
between the two group was statistically significant[RR =
1.33, 95%CI (1.18-1.50), P < 0.00001] (Figure 10). Addi-
tionally, when a effective study[17] was removed, the
Figure 4 Effect of telbivudine vs. lamivudine at the end of two-year treatment on Virological response.
Figure 5 Effect of telbivudine vs. lamivudine at the end of one-year treatment on HBeAg seroconversion.
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difference in HBeAg loss rate was still statistically signif-
icantly[67.4% vs. 53.3%, RR = 1.26, 95%CI (1.17-1.36), P
< 0.00001].
HBsAg response
Of the eleven included studies, only two studies[13,15]
detected serum HBsAg. One study[15] reported the
HBsAg response at the end of one-year treatment while
the other[13] reported the HBsAg response at the both
end of treatment. The results of the study showed the
HBsAg response rate for LdT group was 4.5%, while the
LAM group response rate was 4.3% after one-year treat-
ment. The difference of HBsAg response rates between
the two group was similar[RR = 0.96, 95%CI (0.06-
14.37), P = 0.97]. Two studies reported the HBsAg
response rates, but no statistically significant difference
were seen between LdT group and LAM group[1.3% vs.
1.1%, RR = 1.11, 95%CI (0.43-2.85), P = 0.83].
Safety
Four studies[6,7,10,11] reported the viral breakthrough
rate during the one year treatment. The results of the
study showed the viral breakthrough rates for LdT
group and LAM group were 4.8% and 14.8%
respectively. The difference was statistically significantly
[RR = 0.33, 95%CI (0.24-0.45), P < 0.00001]. Only one
study[15] showed the viral breakthrough rate at the end
of two-year treatment, which said the the viral break-
through rate for the LdT group was 24.9%, while the
LAM group response rate was 41.2%. The difference
was statistically significantly[RR = 0.59, 95%CI (0.51-
0.69), P < 0.00001].
Four studies[7,8,10,11] reported the viral resistance
rate during the one year treatment. The results of the
study showed the viral resistance rates for LdT group
and LAM group were 5.2% and 12.8% respectively. The
difference was statistically significantly[RR = 0.41, 95%CI
(0.30-0.55), P < 0.00001]. Only one study[15] showed
the viral resistance rate at the end of two-year treat-
ment, which said the the viral resistance rate for the
LdT group was 20.4%, while the LAM group response
rate was 35.1%. The difference was statistically signifi-
cantly[RR = 0.58, 95%CI (0.49-0.70), P < 0.00001].
Patients reported nonspecific symptoms such as fati-
gue, cough, headache, upper respiratory tract infection.
Five studies reported[6-8,10,11] the adverse events rate
at the end of one-year treatment. The result of the
study were statistically significantly[RR = 1.07, 95%CI
Figure 6 Effect of telbivudine vs. lamivudine at the end of two-year treatment on HBeAg seroconversion.
Figure 7 Effect of telbivudine vs. lamivudine at the end of one-year treatment on HBeAg loss.
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(1.00-1.14), P = 0.04] (Figure 11). And, even when two
low-quality studies[8,11] were removed, the difference
between two groups still statistically significantly. How-
ever one study reporting the adverse events rate at the
end of two-year treatment showed the result were simi-
lar[RR = 1.05, 95%CI (1.00-1.11), P = 0.07]. So it is
interesting results and hard to say whether LdT can
cause more adverse events or not.
Creatine kinase (CK) elevation
Five studies[6-8,10,11] reported Grade 3 or 4 CK eleva-
tions rate at the end of one-year treatment. According
to chi-squared statistic and I square (I2 ), heterogeneity
was assessed and not found to be a concern[Chi2 = 1.42,
df = 4 (P = 0.84); I2 = 0%]. The difference of CK eleva-
tions rates between the two group was statistically sig-
nificant[6.8% vs. 2.8%, RR = 2.38, 95%CI (1.58-3.59), P <
0.0001] (Figure 12). when an effective study[7] or low-
quality[8,11] was removed, the difference in CK eleva-
tions rate was still statistically significantly. Two studies
[13,15] reported Grade 3 or 4 CK elevations at the end
of two-year treatment. The heterogeneity was not a con-
cern, and the difference of CK elevation rates between
the two group was statistically significant[14.8% vs. 4.8%,
RR = 3.11, 95%CI (2.16-4.47), P < 0.0001] (Figure 13).
So increased CK occurred more frequently during telbi-
vudine treatment during clinical trials.
Discussion
Although new approved powerful agents like entecavir
and tenofovir are available now in certain countries,
there are challenges ahead to be used widely. First, the
prevalence of chronic HBV infection varies greatly in
different parts of the world. Based on the prevalence of
HBV surface antigen(HBsAg) carrier rate in the general
population, sub-Saharan African, East Asian and Alas-
kan populations are classified as having high HBV ende-
micity[18] (HBsAg carriage > 8%). However the majority
of countries in those areas have low-income economies,
and the infrastructure of the healthcare system is not
satisfactory. There are limitations in the reimbursement
of anti-HBV therapy, either in the selection of agent or
the duration of dosing. Therefore, lamivudine and telbi-
vudine with low costs are still widely used[19]. Second,
tenofovir is a new approved agents which hasn’t been
introduced to lots of low-income economy countries
like China. So lamivudine and telbivudine are more
widely used in treatment of CHB.
In this systematic review, we focus on the compari-
son of the efficay of lamivudine and telbivudine in the
Figure 8 Effect of telbivudine vs. lamivudine at the end of two-year treatment on HBeAg loss.
Figure 9 Effect of telbivudine vs. lamivudine at the end of one-year treatment on Therapeutic response.
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Figure 10 Effect of telbivudine vs. lamivudine at the end of two-year treatment on Therapeutic response.
Figure 11 Effect of telbivudine vs. lamivudine at the end of one-year treatment on adverse events.
Figure 12 Effect of telbivudine vs. lamivudine at the end of one-year treatment on CK elevation.
Figure 13 Effect of telbivudine vs. lamivudine at the end of two-year treatment on CK elevation.
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treatment of CHB. The results showed that at the end
of one-year treatment, LdT was better than LAM at
the biochemical response, virological response, HBeAg
loss, therapeutic response, while less than at the viral
breakthrough and viral resistance, but there was no
significant difference in the HBeAg seroconversion and
HBsAg response. However, the difference between
one-year treatment and two-year treatment was that
LdT was better than LAM at the HBeAg seroconver-
sion. So the rate of HBeAg seroconversion increased
with prolonged treatment significantly. The result of
this systematic review showed telbivudine had greater
antiviral efficacy than did lamivudine. Nonetheless the
rate of virological response, HBeAg loss, viral
breakthrough, viral resistance, adverse events and crea-
tine kinase increased while the biochemical response,
therapeutic response and HBsAg response decreased
with prolonged treatment(Figure 14, Figure 15). Parti-
cular attention should be paid to the adverse events.
This systematic review indicated that the frequencies
of adverse events were more for patients who received
telbivudine than for those who received lamivudine,
and increased with the prolonged treatment. Especially,
Grade 3 or 4 increased CK occurred more frequently
during telbivudine treatment. The RR was 3.11 and
95% CI was between 2.16 and 4.47. In contrast,
LAM is more tolerable than LdT and has fewer side
effects.
Figure 14 End of one-years and two-years in biochemical response, virological response, HBeAg seroconversion, HBeAg loss,
therapeutic response.
Figure 15 End of one-years and two-years in HBsAg response, viral breakthrough, viral resistance, adverse events and creatine kinase.
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The limitations of the systematic review warrant some
discussion. First, the methodological of the trials has
limitations. Some studies were not double-blinded. The
lack of blinding could affect the outcomes assessed[20].
Even one study[9] didn’t perform at random which can
lead selection bias[21]. Second, the potentially important
limitation of systematic review is publication bias, the
fact that not all research is published. Compared to
positive studies, negative studies may be less likely to be
published and more likely to take longer to be pub-
lished, which can affect the validity of meta-analysis in
this review[22]. Besides only publish in English and Chi-
nese studies were included in this systematic review
which may cause language bias. The manual search of
many medical journals published in different languages
will help to reduce this bias[23]. Additional issues
include small trial sizes and a high rate of studies that
were conducted in China.
In summary, LdT was superior in inhibiting HBV
replication and preventing drug resistance as compared
to LAM for CHB patients. But LdT may occur more
nonspecific adverse events and can lead more CK eleva-
tion than LAM. It is thus recommended that the LdT
could be used as an option for patients but adverse
events, for example CK elevation, must be monitored.
More high-quality, well-designed, randomized con-
trolled, multi-center trails that are adequately powered
are clearly needed to guide evolving standards of care
for CHB.
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